Prior notification of a concentration (Case M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT)
Date: 2024-11-11
Institutions: Directorate-General for Competition, European Commission
Subjects: biotechnology, economic concentration, health care, holding company, illness, investment company, merger control, pharmaceutical industry, provision of services, therapeutics








C_202406837EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/6837


11.11.2024






Prior notification of a concentration
(Case M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT)
(Text with EEA relevance)
(C/2024/6837)


1.   
On 31 October 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Novo Holdings A/S (‘Novo Holdings’, Denmark),










—


Novo Nordisk A/S (‘Novo Nordisk’, Denmark), controlled by Novo Holdings,










—


Catalent, Inc. (‘Catalent’, U.S.).




Novo Holdings will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Catalent. Subsequently, Catalent’s sites in Brussels (Belgium), Anagni (Italy), and Bloomington (U.S.) will be transferred to Novo Nordisk.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Novo Holdings is a holding and investment company responsible for the management of the assets of Novo Nordisk Fonden, which owns 100 % of the shares of Novo Holdings, through strategic investments in the life sciences and related areas and through investments of a financial and venture capital nature in a broad portfolio of companies,










—


Novo Nordisk is a global healthcare company with a focus on developing treatments for metabolic disorders such as diabetes and obesity, as well as chronic diseases such as inter alia, haemophilia and growth disorders,










—


Catalent is a global contract development and manufacturing organisation which provides third-party development and manufacturing solutions to companies in the pharmaceutical, biotech, and consumer health industries.






3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.



4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  
            OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).


ELI: http://data.europa.eu/eli/C/2024/6837/oj
ISSN 1977-091X (electronic edition)